# Allergan

# SAFETY DATA SHEET

Revision Date 02-Oct-2018 Version 11

# 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Chemical Name Pilocarpine Hydrochloride

Other means of identification

Product Code 54-71-7 Synonyms None

Recommended use of the chemical and restrictions on use

Recommended Use Pharmaceutical

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

# Details of the supplier of the safety data sheet

### Manufacturer

Allergan plc 5 Giralda Farms Madison, NJ USA 07940 +1-800-272-5525

E-mail address SDS@Allergan.com

Emergency telephone number

Emergency Telephone Call CHEMTREC Day or Night

Within USA or Canada: 1-800-424-9300

Outside USA and Canada: +1-703-741-5970 (collect calls accepted)

# 2. HAZARDS IDENTIFICATION

### Classification

# **OSHA Regulatory Status**

This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

| Acute toxicity - Oral                     | Category 2  |
|---|-------------|
| Acute toxicity - Inhalation (Dusts/Mists) | Category 2  |
| Reproductive toxicity                     | Category 1B |
| Effects on or via lactation               | Yes         |

### Label elements

# **Emergency Overview**

### Danger

### Hazard statements

H360 - May damage fertility or the unborn child H362 - May cause harm to breast-fed children



Appearance powder

Physical state Solid

**Odor** Odorless

**Chemical Name** 

Pilocarpine Hydrochloride

**Symptoms** 

The most frequent adverse experiences associated with this medication are the consequence of expected pharmacologic effects of the medication. This includes: sweating, nausea, rhinitis, diarrhea, chills, flushing, urinary frequency, dizziness, asthenia. In addition the following adverse events (less than or equal to 3% incidence) were reported at dosages at 15-30 mg/day in the controlled clinical trials: headache, dyspepsia, lacrimation, edema, abdominal pain, amblyopia, vomiting, pharyngitis, hypertension.

**Chemical Name** 

Pilocarpine Hydrochloride

**Medical Conditions Aggravated by Exposure** 

This medication is contraindicated in patients with uncomfortable asthma, known hypersensitivity to pilocarpine, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure) glaucoma.

### **Precautionary statements**

P301 + P310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

P321 - Specific treatment (see supplemental first aid instructions on this label)

P330 - Rinse mouth

P271 - Use only outdoors or in a well-ventilated area

P284 - Wear respiratory protection

P310 - Immediately call a POISON CENTER or doctor/physician

P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing

P320 - Specific treatment is urgent (see .? on this label)

P403 + P233 - Store in a well-ventilated place. Keep container tightly closed

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P405 - Store locked up

P501 - Dispose of contents/ container to an approved waste disposal plant

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P201 - Obtain special instructions before use

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P263 - Avoid contact during pregnancy/while nursing

P264 - Wash face, hands and any exposed skin thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P308 + P313 - IF exposed or concerned: Get medical advice/attention

### Other Information

Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

| Chemical Name             | CAS No. | EINECS    | Weight-% |
|---------------------------|---------|-----------|----------|
| Pilocarpine Hydrochloride | 54-71-7 | 200-212-5 | 100      |

<sup>\*</sup>The exact percentage (concentration) of composition has been withheld as a trade secret.

# 4. FIRST AID MEASURES

### First aid measures

**General advice** Immediate medical attention is required.

Eye contact Immediately flush with plenty of water. After initial flushing, remove any contact lenses and

continue flushing for at least 15 minutes. Keep eye wide open while rinsing. Call a physician

immediately.

**Skin Contact** Immediate medical attention is required. Wash off immediately with soap and plenty of

water while removing all contaminated clothes and shoes.

**Inhalation** Immediate medical attention is required. Remove to fresh air. If not breathing, give artificial

respiration. Avoid direct contact with skin. Use barrier to give mouth-to-mouth resuscitation.

Ingestion Do NOT induce vomiting. Call a physician or poison control center immediately. Never give

anything by mouth to an unconscious person. Drink plenty of water.

### **Chemical Name**

Pilocarpine Hydrochloride

### Note to physicians

Patients with significant cardiovascular disease may be unable to compensate for transient changes in hemodynamics of rhythm induced by this medication. Pulmonary edema has been reported as a complication of pilocarpine toxicity from high ocular doses given for acute angle-closure glaucoma. This medication should be administered with caution in and under close medical supervision of patients with significant cardiovascular disease. This medication has been reported to cause visual blurring which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception. Caution should be advised while driving at night or performing hazardous activities in reduced lighting. This medication has been reported to increase airway resistance. bronchial smooth muscle tone and bronchial secretions. This medication should be administered with caution to and under close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease requiring pharmacotherapy. This medication should be administered with caution to patients with known or suspected cholelithiasis or biliary tract disease. Contractions of the gallbladder of biliary smooth muscle could precipitate complications including cholecystitis, cholangitis, and biliary obstruction. This medication may increase ureteral smooth muscle tone and could theoretically precipitate renal colic (or "ureteral reflux"), particularlyin patients with nephrolithiasis. Cholinerigc agonists may have dose-related central nervous system effects. This should be considered when treating patients with underlying cognitive or psychiatric disturbances.

# 5. FIRE-FIGHTING MEASURES

### Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

### Unsuitable extinguishing media

None known.

### Specific hazards arising from the chemical

Some are oxidizers and may ignite combustibles (wood, paper, oil, clothing, etc.).

**Explosion data** 

Sensitivity to Mechanical Impact Not i

Not impact sensitive.

Sensitivity to Static Discharge Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition

source is a potential dust explosion hazard.

### Protective equipment and precautions for firefighters

Wear self-contained breathing apparatus and protective suit.

# 6. ACCIDENTAL RELEASE MEASURES

spill/leak.

Other Information Do not get water inside containers or in contact with substance.

**Environmental precautions** Prevent further leakage or spillage if safe to do so. Prevent product from entering drains.

See Section 12 for additional ecological information.

Methods for containment Prevent further leakage or spillage if safe to do so. Cover powder spill with plastic sheet or

tarp to minimize spreading. Dike far ahead of liquid spill for later disposal.

Methods for cleaning up

Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp

to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly.

### 7. HANDLING AND STORAGE

**Advice on safe handling**Avoid contact with skin, eyes or clothing. Use personal protective equipment as required.

Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray.

Do not eat, drink or smoke when using this product.

Storage Conditions Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of

children.

Incompatible materials None known based on information supplied.

# 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

**Exposure Guidelines**This product, as supplied, does not contain any hazardous materials with occupational

exposure limits established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering Controls The following requirements list high level controls designed to control exposure below the

OEL. More specific requirements may apply.

Individual protection measures, such as personal protective equipment

PPE The following high level PPE requirements assume Engineering Controls that reduce

exposure below the limit are not in place. More specific requirements may apply

**Eye/face protection** Tight sealing safety goggles.

**Skin and body protection**During medical administration of this product, medical latex or nitrile gloves should be worn

to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab

coat, etc.).

**Respiratory protection**Respiratory protection is generally not needed during routine conditions of use of this

product. If respiratory protection is needed, use only respiratory protection authorized under

appropriate regional regulations.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

### Information on basic physical and chemical properties

Physical stateSolidAppearancepowderColorwhiteOdorOdorless

Odor threshold No information available

<u>Property</u> <u>Values</u>

pH No information available

Melting point/freezing point 202 °C / 396 °F

Boiling point / boiling range No information available

Flash point No information available

Evaporation rate No information available

Flammability (solid, gas) No information available

Flammability Limit in Air

Upper flammability limit: No information available Lower flammability limit: No information available No information available Vapor pressure Vapor density No information available **Specific Gravity** No information available Water solubility No information available Solubility in other solvents No information available Partition coefficient No information available **Autoignition temperature** No information available **Decomposition temperature** No information available **Explosive properties** No information available **Oxidizing properties** No information available

**Other Information** 

Molecular weight 244.75

VOC Content (%)No information availableDensityNo information availableBulk densityNo information available

# 10. STABILITY AND REACTIVITY

Reactivity

Not defined As Reactive substance

**Chemical stability** 

Stable under normal conditions.

Possibility of Hazardous Reactions

None under normal processing.

**Conditions to avoid** 

Aerosol formation.

**Incompatible materials** 

None known based on information supplied.

**Hazardous Decomposition Products** 

None known based on information supplied.

# 11. TOXICOLOGICAL INFORMATION

### Information on likely routes of exposure

### **Acute toxicity**

| Chemical Name             | Oral LD50         | Dermal LD50 | Inhalation LC50 |
|---------------------------|-------------------|-------------|-----------------|
| Pilocarpine Hydrochloride | 200 mg/kg (mouse) | N/A         | N/A             |

Delayed and immediate effects as well as chronic effects from short and long-term exposure

| Chemical Name             | Germ cell mutagenicity    | Carcinogenicity               | Reproductive toxicity         | Effects on or via lactation  |
|---------------------------|---------------------------|-------------------------------|-------------------------------|------------------------------|
| Pilocarpine Hydrochloride | No information available. | Animal studies in mice didn't | Animal studies in mice, rats  | It is not known whether this |
|                           |                           | show carcinogenicity at any   | and dogs have shown           | drug is excreted in human    |
|                           |                           | dose and studies in rats      | fertility impairment which    | milk. Because of the         |
|                           |                           | showed tumorigenicity only    | was likely due to decrease in | potential for tumorigenicity |
|                           |                           | at doses significantly higher | spermatogenesis. Animal       | shown for albuterol in some  |
|                           |                           | than the equivalent human     | studies in rats have shown    | animal studies, a decision   |
|                           |                           | therapeutic dose.             | an increase of skeletal       | should be made whether to    |
|                           |                           |                               | variations, body weight       | discontinue nursing or to    |
|                           |                           |                               | decrease, increased still     | discontinue the drug, taking |
|                           |                           |                               | born birth at doses           | into account the importance  |
|                           |                           |                               | significantly higher than the | of the drug to the mother.   |
|                           |                           |                               | equivalent human              |                              |
|                           |                           |                               | therapeutic dose.             |                              |

Chronic toxicity
Target Organ Effects

Prolonged or repeated exposure increases the risk. Possible risk of irreversible effects.

Central nervous system, Gastrointestinal tract (GI), heart, Respiratory system.

Numerical measures of toxicity - Product Information

The following values are calculated based on chapter 3.1 of the GHS document .

ATEmix (oral) 5 mg/kg ATEmix (inhalation-dust/mist) 0 mg/l

# 12. ECOLOGICAL INFORMATION

**Ecotoxicity** 

Other adverse effects No information available

# 13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national and local laws and

regulations.

Contaminated packaging Do not reuse container. Dispose of contents/containers in accordance with local

regulations.

# 14. TRANSPORT INFORMATION

DOT Not regulated

TDG Not regulated

ICAO (air) Not regulated

IATA Not regulated

IMDG Not regulated

ADR Not regulated

Not regulated

Not regulated

Not regulated

Not regulated

### 15. REGULATORY INFORMATION

**International Inventories** 

TSCA Listed
DSL/NDSL Listed
EINECS/ELINCS Listed

### Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

# **US Federal Regulations**

### **SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372

### SARA 311/312 Hazard Categories

Acute health hazard Yes
Chronic Health Hazard Yes
Fire hazard No
Sudden release of pressure hazard No
Reactive Hazard No

### **CWA (Clean Water Act)**

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42)

### **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material

### **US State Regulations**

### **California Proposition 65**

This product does not contain any Proposition 65 chemicals

### **U.S. State Right-to-Know Regulations**

### 16. OTHER INFORMATION

Revision Date 02-Oct-2018

Revision Note No information available

<u>Disclaimer</u>

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

**End of Safety Data Sheet**